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Abstract The aim of this study was to characterize myelin
loss as one of the features of white matter abnormalities
across three common dementing disorders. We evaluated
post-mortem brain tissue from frontal and temporal lobes
from 20 vascular dementia (VaD), 19 Alzheimer’s disease
(AD) and 31 dementia with Lewy bodies (DLB) cases and
12 comparable age controls. Images of sections stained with
conventional luxol fast blue were analysed to estimate
myelin attenuation by optical density. Serial adjacent sec-
tions were then immunostained for degraded myelin basic
protein (dMBP) and the mean percentage area containing
dMBP (%dMBP) was determined as an indicator of myelin
degeneration. We further assessed the relationship between
dMBP and glutathione S-transferase (a marker of mature
oligodendrocytes) immunoreactivities. Pathological diag-
nosis signiﬁcantly affected the frontal but not temporal lobe
myelin attenuation: myelin density was most reduced in
VaD compared to AD and DLB, which still signiﬁcantly
exhibited lower myelin density compared to ageing con-
trols. Consistent with this, the degree of myelin loss was
correlated with greater %dMBP, with the highest %dMBP
in VaD compared to the other groups. The %dMBP was
inversely correlated with the mean size of oligodendrocytes
in VaD, whereas it was positively correlated with their
density in AD. A two-tier regression model analysis con-
ﬁrmed that the type of disorder (VaD or AD) determines the
relationship between %dMBP and the size or density of
oligodendrocytes across the cases. Our ﬁndings, attested by
the use of three markers, suggest that myelin loss may
evolve in parallel with shrunken oligodendrocytes in VaD
but their increased density in AD, highlighting partially
different mechanisms are associated with myelin degener-
ation, which could originate from hypoxic–ischaemic
damage to oligodendrocytes in VaD whereas secondary to
axonal degeneration in AD.
Keywords Alzheimer’s disease   Myelin   Myelin basic
protein   Oligodendrocyte   White matter   Vascular
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Introduction
The pathogenesis of white matter (WM) changes is unclear
but they frequently although not always coincide with
cerebrovascular risk factors such as hypertension, athero-
sclerosis and diabetes as is seen in patients with vascular
dementia (VaD) [29]. Disturbances in cerebrospinal ﬂuid
production, disruption in blood–brain barrier permeability
to macromolecules, and cerebral oedema [23, 38] have
been cited as important causes in the development of WM
changes. WM attenuation is also frequently observed in
neurodegenerative disorders such as Alzheimer’s disease
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DOI 10.1007/s00401-009-0635-8(AD) [42] and dementia with Lewy bodies (DLB) [31]. On
magnetic resonance (MR) imaging, such changes are
apparent as WM lesions which increase with older age [18]
and particularly so in AD and DLB compared to ageing
controls, though to a lesser extent than in VaD [5].
Quantitative post-mortem MR imaging also reﬂects the
severity of the neuropathological changes in the WM [21].
Recent diffusion tensor imaging studies suggest that the
WM microstructure disintegrates with age, in particular,
ﬁbre populations within prefrontal region and internal
capsule [6, 41].
The WM may be affected by hypoxic–ischaemic
damage or alternatively by secondary demyelination
subsequent to axonal degeneration due to neuronal damage
[15]. A previous clinicopathological study indicated that
compared to AD, patients with VaD showed widespread
diffuse changes, including spongiosis and arteriolosclero-
sis, along with e ´tat crible ´ and myelin loss [16], suggesting
different etiologies of the WM damage between VaD and
AD. However, given the widely accepted fact that VaD and
AD both increase in prevalence with age, frequently occur
concomitantly, and overlap considerably in their symp-
tomatology, pathophysiology, and comorbidity [25, 26],
the WM changes in AD and even DLB may be caused by
related vascular mechanisms. Therefore, our aim here was
to quantify the severity of WM myelin loss and determine
the underlying aetiology of WM abnormalities in VaD
compared to AD and DLB.
To compare WM changes between controls and VaD,
AD, and DLB cases, we used hematoxylin and eosin
(H&E) and luxol fast blue (LFB) staining and immuno-
histochemistry with antibodies against degraded myelin
basic protein (dMBP). In the case of LFB, we developed a
computer-assisted morphometric image analysis to
quantify myelin attenuation in the WM. dMBP immuno-
histochemistry provided an index of WM damage because
the antibody to dMBP recognizes a pathologically exposed
epitope of the human MBP (an 81–87 amino acid
sequence; QDENPVV) in demyelinating diseases such as
multiple sclerosis [34], diffuse WM changes [47], and focal
ischaemic damage (Tomimoto H, unpublished data, 2008).
To assess oligodendrocyte status within the disease groups,
we immunostained selected cases with an antibody against
glutathione S-transferase pi (GSTpi; a marker of oligo-
dendrocytes) to evaluate if there was a relationship
between oligodendrocytic change and WM damage.
Previous studies have thus far reported decreases in oli-
godendrocytes in VaD [1] and in AD [42, 43], although
robust quantitative analysis in a larger series is lacking.
Therefore in this study, we evaluated the integrity of a WM
component and oligodendrocytes using novel markers to
address whether the underlying mechanisms affecting the
WM are similar among the three dementias.
Materials and methods
Subjects, histopathological and immunohistochemical
procedures
Table 1 provides the demographics and the pathological
features of the subjects. All the patients were prospectively
assessed in Newcastle and the duration of clinical disease
ranged between 6 and 12 years. We obtained coronal
blocks of tissue from the frontal and temporal lobes from
the Newcastle Brain Tissue Resource (NBTR) and exclu-
ded cases with pathological diagnoses of co-existing VaD
and AD or VaD and DLB. Thus, 82 cases were included in
this study to select cases for relatively single processes,
which consisted of 12 controls, 31 DLB cases, 19 AD
cases, and 20 VaD cases. Autopsies were performed within
12–36 h after death. The post-mortem intervals between
death and tissue retrieval were not different between the
groups. There were also no differences in the length of
ﬁxation of tissue in formalin between the cases and con-
trols
. Brains were ﬁxed for 4–6 weeks. As previously
described [30], the neuropathological diagnoses of VaD
[28], AD [9, 37], and DLB [35] were made by thorough
histopathological examination of extensively sampled
brain sections. The clinical study had ethical approval from
the local Newcastle Ethics committees and all participants
gave written consent to brain tissue donation. Use of brain
tissue was also approved by the local research ethics
committee of the Newcastle upon Tyne Hospitals NHS
Foundation Trust and the NBTR committee.
Ten and 20-lm thick parafﬁn-embedded tissue sections
were cut from the frontal lobe at the level of the olfactory
bulbs and the temporal lobe at the level of the anterior
hippocampus and stained for H&E and LFB (20 lm) and
for immunohistochemistry (10 lm). To minimize vari-
ability in LFB staining and immunohistochemical intensity,
control sections were included, tissue sections were pre-
pared by the same technician and stained with or using
freshly prepared tinctorial and buffer solutions.
Assessment of myelin density
Myelin density was determined in a large series of LFB-
stained serial coronal sections from cases and controls to
select representative regions of interest (ROI) for analyses.
The analyses were performed essentially as previously
described [51]. To determine the myelin index, the WM was
outlined automatically using the wand tool. When the bor-
der between the neocortex and the WM was obscured due to
severe myelin loss, the WM was outlined manually using
the semiautomatic trace tool instead of the wand tool. Any
incidental border region of the cortex mixed in the outlined
WM area was excluded from the analysis (Fig. 1, asterisk).
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sponding to the staining intensity, from the point 0–127 (0,
white; 255, black) was divided into four quartiles (the ﬁrst
quartile 0–29, the second 30–62, the third 63–94, and the
fourth 95–127). The percent area (%area) for each quartile
was calculated. The median grey level of each quartile
(14.5, 46.0, 78.5, and 111.0), an estimate for the staining
intensity, was then multiplied by %area/100 in each
quartile, which gave the total myelin index [51]. Braak
staging [8] and plaque burden scores were used to explore
the relationship with the myelin index. Chi-square analysis
was performed to determine if higher Braak stage (CIV)
affected myelin index (cut-off score = median value of
myelin index, 44.0 for the frontal lobe; 40.0 for the temporal
lobe) or amyloid score (none/sparse or moderate/severe) in
the combined cases of AD and DLB (28 cases with Braak
Table 1 Age, gender and disease severity of the groups
Parameter Controls DLB AD VaD
Demographic details
N 12 31 19 20
Age (±SD) 75.6 ± 7.8 79.1 ± 5.7 85.5 ± 5.5 81.0 ± 8.5
Age range (years) 61–92 64–89 75–96 67–93
Gender (M/F) 6/6 14/17 7/12 10/10
Pathological features
Mean Braak stage 1.0 ± 1.0 2.3 ± 1.0 4.9 ± 0.8 1.3 ± 0.7
Neuritic plaque density
a (per mm
2)2 ± 12 1 ± 32 7 ± 47 ± 2
Lewy body pathology (ubiquitin score) \1 7.2 ± 2.6 \1 \1
Lewy body pathology (a-synuclein score) \1 12.5 ± 5.0 \1 \1
Number of vascular lesions (range) 0–1 0–3 0–3 3–15
Degree of CAA (range) 0–1 0–4 1–4 0–4
Frontal myelin index* 51.1 ± 9.5 41.5 ± 8.5 35.9 ± 11.1 26.5 ± 9.0
Temporal myelin index 37.3 ± 10.1 32.7 ± 13.4 35.2 ± 11.0 34.4 ± 11.9
Unless otherwise stated numbers show mean values with standard deviation (±SD). AD subjects were signiﬁcantly older than controls and DLB
(P\0.01). Selected cases stained for amyloid b protein immunoreactivity also showed the severity of neuritic plaque burden in AD and DLB
was comparable to the phases 4 and 5 staging described by Thal et al. [46] and the BrainNet Europe Consortium [3]. The presence of Lewy body
pathology was determined by ubiquitin and a-synuclein immunostaining [35]. The number of vascular lesions and degree of CAA were recorded
according to the Vonsattal grading as previously described [28, 40]
* Signiﬁcant difference (P\0.05) between any two groups
a Neuritic plaque densities were comparable to the CERAD ratings in that moderate to severe scores were evident in 95% of AD and 74% of
DLB cases
Fig. 1 Quartile analysis of
LFB-stained section from the
frontal lobe of a VaD patient
(74 years). The WM was
outlined in green and the grey
levels within the WM were
divided into four quartiles. The
area percentage (%area) for
each quartile was calculated
(labelled in red). Myelin index
was then calculated for each
case and control (see
‘‘Methods’’) (scale bar 1 cm)
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123stage 0 through III and 22 cases with Braak stage IV through
VI). The H&E-stained slides were examined in parallel but
independently of the ﬁndings in the LFB images or case
diagnosis. The WM damage was categorized as one of the
following four grades as previously described [43] and
corroborated by quantitative biochemical data [14]: (1)
normal, normal WM; (2) mild, no appreciable reduction in
axonal meshwork density and easily recognized long axons
with occasional axonal debris and a slightly increased
number of reactive astrocytes; (3) moderate, a slight
reduction of axonal meshwork density and a reduction of
oligodendroglial cell nuclei and a further increased number
of reactive astrocytes; and (4) severe, a marked reduction of
myelin, axons and oligodendroglial cell nuclei with rela-
tively marked astrocytic reaction and loosely scattered
macrophages, but no complete cerebral infarct. When sev-
eral grades were observed in one section, the dominant
grade represented the section.
Assessment of dMBP staining
Frontal sections from 59 cases (controls n = 8, DLB
n = 18, AD n = 14, VaD n = 19) with WM
area[15 mm
2 were stained with rabbit anti-dMBP sera
(AB5864, Millipore, Billerica, MA, USA) essentially as
previously described [51] using the Vectastain ABC Sys-
tem [27]. Images of 15–22 randomly selected ROIs in the
WM were captured and then analysed [51]. The percentage
immunostained area was measured within each ﬁeld, which
was averaged to yield %dMBP for all the sections.
Infarcted areas were always excluded from the analysis
because of the entirely different patterns of dMBP staining.
All of the above analyses were performed blind to the
diagnosis by labelling the sections with arbitrary numbers.
Assessment of GSTpi staining
Serial sections from ﬁve cases of VaD and AD each and
three cases of DLB immediately adjacent to those stained
for dMBP were stained with an antibody against GSTpi
(Thermo Fisher Scientiﬁc Anatomical Pathology, Chesh-
ire, UK) to determine the density (number of
oligodendrocytes/mm
2) and the mean size (lm
2) of oli-
godendrocytes. For such staining, 15–22 images of the
ROI as for dMBP staining were similarly captured and
analysed using computer-assisted analysis. Our pre-
liminary data suggested that staining quality exponentially
diminished with prolonged postmortem delay, especially
when it exceeded 30 h. Some of the sections showed high
background and reduced contrast, making it difﬁcult to
correctly identify oligodendrocytes. However, all cells
with stained area of 4.2–25.3 lm
2 (40–240 pixels) were
counted after testing for accuracy for oligodendrocyte size
rather than macrophages or other cells. Non-speciﬁc
reactivities such as in blood vessel walls, mostly linear in
shape with major axis larger than 24 pixels and minor axis
smaller than 6 pixels, and macrophages were distinguished
from the oligodendrocytic staining and automatically
excluded from the analysis. In addition to GSTpi, we
tested with success a range of other antibodies to detect
mature oligodendrocytes including those to 20,30-cyclic
nucleotide 30-phosphodiesterase (clone 11-5b, Sigma-
Aldrich, St. Louis, MO, USA), myelin oligodendrocyte
glycoprotein (courtesy of Prof Richard Reynolds, Imperial
College), Nogo-A (Abcam, Cambridge, UK), OLIG2
(Abcam) and SRY-box containing gene 10, SOX10 (clone
20B7, R&D Systems, Abingdon, UK).
Statistical analysis
Statistical analysis was performed using StatView5.0 (SAS
Institute, Cary, NC, USA). Frontal and temporal myelin
densities were analysed separately. The %area for the ﬁrst
or second quartile, the myelin index, and %dMBP were
compared among the four groups by an unpaired t test.
Frontal and temporal WM were analysed separately for the
%area and myelin index. Pearson correlation analysis was
performed to observe possible correlation of %dMBP with
the %area for the ﬁrst or second quartile, with myelin
index, or with the size/density of oligodendrocytes. Chi-
square analysis was performed to determine any correlation
of myelin index with the Braak stage or plaque density in
the AD and DLB cases combined (all except one DLB case
showed Braak stage C I). A two-level regression model
was also applied to the hierarchical data set, with size or
density of oligodendrocytes as a single outcome and
%dMBP as a response variable that was measured at the
ROI (lower) level, and with age, gender, disease (disease
code; 0 = AD and 1 = VaD), and mean %dMBP as
explanatory variables at the case (higher) level using the
HLM6 software. For all analyses, the level of statistical
signiﬁcance was set at P\0.05.
Results
Correlation between myelin index in LFB and WM
grading by H&E
The myelin indices determined from LFB-stained sections
were grouped according to the four grades (normal, mild,
moderate and severe) of WM damage indicated by H&E
(n = 35). The myelin index decreased with increasing
severity of the WM pathology (Fig. 2). These data showed
remarkable consistency in the assessment of WM damage
between LFB and H&E in the subset of cases.
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in dementing disorders as assessed by LFB staining
The diagnosis signiﬁcantly affected the frontal myelin loss
as assessed by the myelin index (Fig. 3; Table 1). The
%area that fell into the ﬁrst quartile (most severe myelin
loss) increased with the following order: controls
(4.3%)\DLB (18.3%)\AD (34.6%)\VaD (63.1%)
(Fig. 3b). There were signiﬁcant differences between any
two groups except for the marginal signiﬁcance between
controls and DLB. Similarly, the frontal myelin index was
signiﬁcantly different between any two groups with the
following order: controls[DLB[AD[VaD (Table 1;
Fig. 3c), indicating that myelin loss was greatest in the
VaD group. Age did not correlate with the myelin index
(r =- 0.20 for frontal WM; r =- 0.05 for temporal WM).
Chi-square test showed that higher Braak stage (IV, V, and
VI) was signiﬁcantly related to the lower frontal myelin
index (less than 44.0) in the AD and DLB cases combined
(P = 0.048). However, there were no clear correlations
between plaque densities and myelin index.
By contrast, in the temporal lobe, the %area for the ﬁrst
quartile was neither signiﬁcantly different between any of
groups (controls, 33.7%; DLB, 47.4%; AD, 38.1%; and
VaD, 41.2%) nor was the temporal myelin index (Table 1),
although the three dementia groups showed slightly more
WM changes than controls. Chi-square analysis showed no
signiﬁcant association between the Braak stage and tem-
poral myelin index (less than 40.0) in the AD and DLB
cases combined (P = 0.21). There was also no signiﬁcant
correlation between frontal and temporal myelin index in
any single group (P = 0.25 for controls, P = 0.23 for
DLB, P = 0.78 for AD, and P = 0.39 for VaD) or in all
the groups combined (P = 0.75).
Myelin loss in the frontal lobes in dementing disorders
as assessed by dMBP labelling
In the frontal WM of VaD cases, oligodendrocytic cell
bodies of irregular size and myelin sheaths along the axon
were densely stained for dMBP (Fig. 4a). dMBP-positive
myelin sheaths were less frequently observed in AD and
DLB compared to VaD but were still more frequent than in
controls (Fig. 4a). Quantitative analysis showed that
%dMBP was signiﬁcantly greater in VaD than in the other
three groups (Fig. 4b). There was a signiﬁcant inverse
Fig. 2 Boxplot analysis for frontal myelin indices from LFB-stained
sections in cases with microscopically evaluated normal WM (n = 3)
and in those with WM changes categorized as mild (n = 18),
moderate (n = 6), and severe (n = 8) in H&E. The line within the
box indicates the median value. Error bars are drawn at the 5% and
the 95% conﬁdence intervals
Fig. 3 Myelin loss in the frontal lobes in dementing disorders as
assessed by LFB staining. a Representative images of LFB staining in
cases of control (89 years), AD (87 years), DLB (77 years), and VaD
(78 years) (scale bars 1 cm). b The %area for the ﬁrst quartile in the
four groups (Table 1). Differences were signiﬁcant between any two
groups except for that between controls and DLB; controls versus
DLB, P = 0.0537; controls versus AD, P = 0.0032; controls versus
VaD, P\0.0001; DLB versus AD, P = 0.0464; DLB versus VaD,
P\0.0001; AD versus VaD, P = 0.0045. c The frontal myelin index
in the four groups. Differences were signiﬁcant between any two
groups: controls versus DLB, P = 0.0027; controls versus AD,
P = 0.0005; controls versus VaD, P\0.0001; DLB versus AD,
P = 0.0473; DLB versus VaD, P\0.0001; AD versus VaD,
P = 0.0060. Vertical bars represent mean ± SE
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123correlation between the %dMBP and the myelin index in all
the 59 cases combined (r =- 0.823, P\0.0001) (Fig. 4c).
Consistent with this, the %dMBP positively correlated with
the %area for the ﬁrst quartile of myelin density (r = 0.823,
P\0.0001) and negatively correlated with that for the
second quartile (r =- 0.777, P\0.0001).
Oligodendrocyte status with GSTpi
immunohistochemistry
The %dMBP was signiﬁcantly but inversely correlated
with the size of oligodendrocytes in VaD cases (r =- 0.70,
P = 0.0017; r =- 0.48, P = 0.023; r =- 0.72, P =
0.0008; r =- 0.76, P\0.0001; r =- 0.79, P\0.0001)
(Fig. 5a). This robust inverse correlation was also shown
when all the ﬁve cases were combined (r =- 0.628,
P\0.0001). In the areas for the ﬁrst quartile where dMBP
staining was extensive, a number of small, irregularly
shaped oligodendrocytes were labelled for dMBP as well as
GSTpi, indicating that damaged oligodendrocytes were
shrunken (Fig. 5c). In two VaD cases, the %dMBP sig-
niﬁcantly correlated with the density of oligodendrocytes
(Fig. 5b, solid lines; r =- 0.64, P = 0.0010; r =- 0.54,
P = 0.025), while in other three VaD cases it did not reach
statistical signiﬁcance (Fig. 5b, dotted lines). In the
infarcted area with macrophage inﬁltration, the GSTpi-
positive cells mostly disappeared, possibly reﬂecting loss
of oligodendrocytes after severe ischaemia (Fig. 5c,
rightmost panels).
By contrast, the %dMBP did not correlate with size of
oligodendrocytes in the four AD cases (Fig. 6a, dotted
lines), but even positively correlated in one AD case
(r = 0.56, P = 0.018) (Fig. 6a, solid line). However, the
%dMBP correlated with the density of oligodendrocytes in
all ﬁve AD cases (r = 0.84, P\0.0001; r = 0.68,
P = 0.004; r = 0.82, P\0.0001; r = 0.85, P\0.0001;
r = 0.87, P\0.0001) (Fig. 6b), which was opposite to the
trend in VaD cases. Oligodendrocytes were apparently not
shrunken but the density of GSTpi-positive oligodendro-
cytes was increased (Fig. 6c). When all the ﬁve AD cases
were combined, a signiﬁcant correlation was shown
between %dMBP and the density of oligodendrocytes
(r = 0.652, P\0.0001). A two-tier regression analysis
showed that the absolute value of the T ratio (regression
coefﬁcient; SE) was highest for the ‘disease’ variable
(disease code; 0 = AD and 1 = VaD). This analysis
showed the disease effects (VaD or AD) mainly determine
the relationship between the %dMBP and the size or den-
sity of oligodendrocytes rather than age or gender across
the cases. In terms of the ‘size’ of oligodendrocytes as an
outcome variable, the deviance was the lowest (151.29)
when only ‘disease’ was introduced to explanatory vari-
ables (coefﬁcient, -2.45; SE, 0.40; P\0.001), while in
terms of the ‘density’ of oligodendrocytes, the deviance
was the lowest (160.96) when both ‘disease’ (-708.0;
241.8; 0.023) and ‘patient age’ (21.3; 8.95; 0.244) were
introduced to them. No other parameter estimates reached
statistical signiﬁcance.
In the DLB cases, the results were variable: in one case,
the size of oligodendrocytes was inversely correlated with
Fig. 4 Myelin damage in the frontal lobes in dementing disorders as
assessed by novel dMBP labelling. a Representative images of dMBP
staining in cases of control (89 years), AD (87 years), DLB
(77 years), and VaD (78 years) (scale bars 100 lm). Inset in VaD
shows degenerative dMBP-positive myelin sheaths along the axon
(scale bar 50 lm). b %dMBP in the four groups. Vertical bars
represent mean ± SE. Differences were signiﬁcant between any two
groups: controls versus DLB, P = 0.0160; controls versus AD,
P = 0.0029; controls versus VaD, P\0.0001; DLB versus AD,
P = 0.0331; DLB versus VaD, P\0.0001; AD versus VaD,
P = 0.0044. c An inverse correlation between the %dMBP and the
myelin index in the 59 cases combined (r =- 0.823, P\0.0001)
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in the other two cases. The density of oligodendrocytes was
also not correlated with %dMBP (not shown).
Discussion
We utilized computer-assisted analysis to quantify myelin
loss in brain tissues labelled with LFB and also developed a
method to visualize damaged WM using the commercially
available dMBP antibody [34, 47]. Myelin loss in the
frontal lobes, as assessed by LFB and veriﬁed with H&E
staining, was most severe in VaD, less so in AD and DLB,
but still greater than in elderly controls. We also showed
that frontal but not temporal WM changes appear as the
pathological correlates of non-advanced dementia [7, 41,
48]. At more advanced stages of dementia, the temporal
lobe WM exhibits more changes in all dementia types,
particularly in AD, where axonal degeneration with sec-
ondary demyelination is likely more prominent [14].
Previous reports suggest that both the sclerotic changes in
the medullary arteries and the WM changes in subcortical
VaD are most prominent in the frontal lobe whereas least
prominent in the temporal lobe [2, 19]. Thus, the frontal
lobe may be the most susceptible to a hemodynamic
derangement [22], leading to the severe WM changes,
while the temporal lobe is less susceptible, resulting in
smaller differences in temporal WM changes between VaD
and the other groups. This is consistent with the previous
imaging and pathological studies suggesting that frontal
WM is preferentially vulnerable compared to the temporal
WM during ageing and vascular disease [2, 41, 48].
We conﬁrmed that dMBP could be used as an infor-
mative marker of myelin degeneration in cerebrovascular
and neurodegenerative disorders [34, 47] and in rat models
of chronic cerebral hypoperfusion [49]. Furthermore,
Fig. 5 Correlation analysis
between %dMBP and density/
size of oligodendrocytes in the
frontal lobe of VaD cases. a The
%dMBP was inversely
correlated with the size of
oligodendrocytes (OLGs) with
statistical signiﬁcance (blue
points, r =- 0.70; red points,
r =- 0.48; green points, r =
-0.72; light-blue points, r =
-0.76; brown points,
r =- 0.79). Each point
represents a ROI (n = 20–22)
within WM per Fig. 3a. b The
%dMBP inversely correlated
with the density of
oligodendrocytes in two VaD
cases with statistical
signiﬁcance (red points, r =-
0.64; brown points, r =- 0.54)
but not in the others. c Images
for dMBP and GSTpi in two
adjacent sections in a 78-year-
old patient with VaD, showing
that increased myelin damage
(from left to right panels) is
accompanied by shrunken
oligodendrocytes. The infarcted
areas with dMBP-positive
macrophages (arrows) as shown
in the rightmost panels were
excluded from the dMBP
analysis. Magniﬁed images
of GSTpi-positive
oligodendrocytes are
shown in insets
(scale bars 50 lm)
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dMBP or GSTpi suggest that differential mechanisms
underlie WM damage between VaD and AD. The WM
damage may originate from hypoxic–ischaemic damage to
oligodendrocytes in VaD whereas secondary to axonal
degeneration in AD, although the two pathologies at least
partially overlap. Our observations on differential myelin
loss between the dementias are also consistent with in vivo
MR studies of WM lesions [5, 11].
We noted areas of severe WM changes even in AD, i.e.
the WM area that falls into the ﬁrst quartile and the focal
area with high %dMBP, which suggests that severe hyp-
operfusive injury or oligaemia [17] could have occurred in
these cases. However, severe ischaemia should lead to
infarcts and decreased numbers of oligodendrocytes, which
were not evident in the AD cases, partially because cases
with co-existing VaD and AD were excluded from this
study. A more plausible explanation is that the axons of the
neocortical degenerating neurons also degenerate severely
enough to provoke severe WM changes in AD [36]. These
WM changes may be followed by recruitment of
oligodendrocyte progenitor cells (OPCs) and their differ-
entiation to mature oligodendrocytes [45, 50]. Such a
restorative mechanism may represent attempted remyeli-
nation of the WM, which could partially explain the
differential degrees of WM damage between AD and VaD.
Fig. 6 Correlation analysis
between %dMBP and density/
size of oligodendrocytes in the
frontal lobe of AD cases. a The
%dMBP did not signiﬁcantly
correlate with the size of
oligodendrocytes (OLGs) in two
AD cases but it did in one AD
case (r = 0.56). Each point
represents a ROI (n = 20–22)
within WM per Fig. 3a. b The
%dMBP signiﬁcantly correlated
with the density of
oligodendrocytes (blue points,
r = 0.84; red points, r = 0.68;
green points, r = 0.82; light-
blue points, r = 0.85; brown
points, r = 0.87). c Images for
dMBP and GSTpi in two
adjacent sections in an 87-year-
old patient with AD, showing
that increased myelin damage
(from left to right panels) is
accompanied by increased
density of oligodendrocytes
(scale bars 50 lm)
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123In contrast to the ﬁndings here, previous observations
suggested that WM disease in AD entails reduction in
number of oligodendrocytes [42, 43]. The conﬂicting
results could be accounted for by the differences in patient
selection or duration of disease severity, and the method-
ology used including different approaches to the computer-
assisted analyses [42, 43].
Our ﬁndings suggest that oligodendrocytes shrink
because of ischaemia or oligaemia in the WM as even
known from older morphological descriptions [39]. The
shrinkage of oligodendrocytes may be a preliminary step
towards cell death in VaD. It is plausible that ischaemic
injury in the WM involves a chronic hypoxic state [17]i n
VaD and that OPCs are damaged and do not retain the
ability to compensate for the myelin loss. Consistent with
this notion, in an unselected cohort of the elderly, remye-
linating oligodendrocytes were reported to be lost in the
centre of severely demyelinated WM but proliferated in the
adjacent WM [41]. Similarly, in a rat experimental stroke
model, the number of OPCs and mature remyelinating ol-
igodendrocytes reduced in the ischaemic core but were
increased in the periinfarct area [44]. These results suggest
that severe ischaemia leads to unsuccessful remyelination
as a result of impaired recruitment of OPCs, whereas mild
to moderate ischaemia activates the myelin repair system.
This may be comparable to multiple sclerosis, where oli-
godendrocytes become small and non-functional following
long-lasting inﬂammatory insults with subsequent loss of
myelin formation [11, 48].
Intriguingly, in one DLB case, an inverse correlation
between %dMBP and size of oligodendrocytes was evident
in the frontal WM, suggesting that some of the cases bear
underlying WM pathology of vascular origin, although a
caution should be made on interpretation of data on the
basis of a single DLB case. Aged brains, particularly the
oldest ones have pathologies of vascular origin to a great
extent [23]. Consistent with this, some of the non-demen-
ted elderly controls had focal areas of positive dMBP in the
frontal WM. A retrospective study [32] had reported that
frontal lobe WM pathology was more often evident in the
clinically diagnosed DLB [31] than the AD patients but
80% of the DLB cases also exhibited mild to severe AD
pathology [32]. In another study of 96 DLB cases, 38%
who had moderate to severe AD pathology also showed
mild (25%) to severe (7%) cerebrovascular changes
involving the WM [24]. These data collectively suggest
that the neurodegenerative process in DLB is compounded
by AD or vascular pathology.
A possible limitation of this study is that GSTpi is not
the perfect marker of mature oligodendrocytes although we
selected GSTpi over other currently used markers includ-
ing 20,30-cyclic nucleotide 30-phosphodiesterase, MBP,
myelin oligodendrocyte glycoprotein, Nogo-A [20] and
SRY-box containing gene 10 [4] because antibodies to
GSTpi best labelled mature oligodendrocytes in a variety
of human brain specimens using different antigen retrieval
protocols and buffers. We believe biological variability
from case to case may explain this since the marker per-
fectly labelled oligodendrocytes in non-human primate
brain tissue (MI and RNK, unpublished observations)
which was obtained under controlled perfusion and ﬁxation
conditions. Despite this, the evaluation of oligodendrocytes
was validated by dMBP labelling since the antibody used
was unique in detecting ‘unhealthy’ and damaged oligo-
dendrocytes. We suggest that a combination of LFB
staining with immunostaining for dMBP and GSTpi is a
robust approach for analysing WM myelin loss and the
pathogenesis of WM disease, which may also entail
inﬂammatory/immune mechanisms [13].
In conclusion, our study emphasizes high frequency of
frontal WM myelin loss in common dementing disorders,
including VaD, AD, and DLB, and enlightens the ﬁeld with
further clariﬁcation on myelin degradation [12, 16] and the
differential status of oligodendrocytes. We suggest that
myelin loss may evolve in parallel with oligodendrocytic
activation in severely affected regions in AD but with
shrunken oligodendrocytes consistent with a chronic hyp-
oxic state [17] in VaD. Frontal WM changes have
implications for attentional and executive impairments [33,
48] associated with fronto-subcortical circuits in dementing
illness [10]. Our observations indicate that myelin loss in
part occurs due to axonal degeneration [36], which needs to
be similarly revisited across common dementing disorders.
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